EP
PRVB

Eversept Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Eversept Partners’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-73,661
Closed -$891K – 68
2019
Q2 		$891K Buy
+73,661
New +$401K 0.25% 48

Other funds holding PRVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Eversept Partners's PRVB Position: Q3 2019 in Review

Eversept Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2019, closing a stake of 73,661 shares — an estimated $891K sold.

Eversept Partners first reported a position in PRVB in Q2 2019 and held it in 1 quarter. The position peaked at $891K in Q2 2019. 48 funds tracked by Wall St. Rank hold PRVB as of Q3 2019.

  • Eversept Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Eversept Partners sold 73,661 Provention Bio, Inc. Common Stock shares in Q3 2019, an estimated $891K.
  • Eversept Partners first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Eversept Partners's Provention Bio, Inc. Common Stock position peaked at $891K in Q2 2019.
  • 48 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2019.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.